Intraarterial contrast-enhanced ultrasound to predict the short-term tumour response of hepatocellular carcinoma to Transarterial chemoembolization with Lipiodol

Abstract Background Transarterial chemoembolization (TACE) is an effective locoregional therapy in hepatocellular carcinoma (HCC). However, it is difficult to predict the tumour response (TR) of TACE intraprocedurally. The aim of this study was to predict the TR after TACE (1–3 months) in HCC patien...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jiang Bo, Han Peng, Zhu LianHua, Fei Xiang, Luo YuKun
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Carcinoma, hepatocellular Ultrasonography Chemoembolization, therapeutic Contrast-enhanced ultrasound Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/3f57b64702fe474ea729e302f35fe12c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3f57b64702fe474ea729e302f35fe12c
record_format	dspace
spelling	oai:doaj.org-article:3f57b64702fe474ea729e302f35fe12c2021-11-08T11:02:06ZIntraarterial contrast-enhanced ultrasound to predict the short-term tumour response of hepatocellular carcinoma to Transarterial chemoembolization with Lipiodol10.1186/s12885-021-08867-51471-2407https://doaj.org/article/3f57b64702fe474ea729e302f35fe12c2021-11-01T00:00:00Zhttps://doi.org/10.1186/s12885-021-08867-5https://doaj.org/toc/1471-2407Abstract Background Transarterial chemoembolization (TACE) is an effective locoregional therapy in hepatocellular carcinoma (HCC). However, it is difficult to predict the tumour response (TR) of TACE intraprocedurally. The aim of this study was to predict the TR after TACE (1–3 months) in HCC patients using intraprocedural intraarterial contrast enhanced ultrasound (IA-CEUS). Methods In this case-control study, consecutive patients who received TACE in our hospital from September 2018 to May 2019 were enrolled. IA-CEUS was performed before and after TACE. Postoperative contrast-enhanced liver MRI was performed 1–3 months after TACE as the gold standard. According to the modified Response Evaluation Criteria in Solid Tumours (mRECIST), ultrasonic manifestations were compared between the complete remission (CR) group and non-CR group by univariate and multivariate analyses. A logistic predictive model was established and validated, and its diagnostic efficiency was evaluated. Results Forty-four patients with sixty-one lesions were enrolled in the study. Multivariate analysis identified, the risk factors as a large lesion diameter (OR: 1.84; 95% confidence interval [CI]: 1.009, 3.080; P = 0.020), a larger dimension of non-enhancing area in superior mesenteric artery (SMA)-CEUS than the size in B-mode ultrasound preoperatively (OR: 3.379; 95% CI: 1.346,8.484; P = 0.010), presence of corona enhancement in hepatic artery (HA)-CEUS postoperatively (OR: 6.642; 95% CI: 1.214, 36.331; P = 0.029), and decreased corona enhancement thickness (per centimetre) postoperatively (OR: 0.025; 95% CI: 0.006,0.718; P = 0.025). The area under the receiver operating characteristic curve (AUROC) of the predictive model was 0.904 (95% CI: 0.804, 0.966; P < 0.001). The sensitivity, specificity, accuracy, positive predictive value, and negative predictive value were 81.08, 91.67, 85.25, 93.75, and 75.86%, respectively. Leave-one-out cross-validation (LOOCV) showed that the accuracy was 77.05%. Conclusions Intraprocedural IA-CEUS can be used to predict the TR in HCC patients after TACE.Jiang BoHan PengZhu LianHuaFei XiangLuo YuKunBMCarticleCarcinoma, hepatocellularUltrasonographyChemoembolization, therapeuticContrast-enhanced ultrasoundNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Carcinoma, hepatocellular Ultrasonography Chemoembolization, therapeutic Contrast-enhanced ultrasound Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Carcinoma, hepatocellular Ultrasonography Chemoembolization, therapeutic Contrast-enhanced ultrasound Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Jiang Bo Han Peng Zhu LianHua Fei Xiang Luo YuKun Intraarterial contrast-enhanced ultrasound to predict the short-term tumour response of hepatocellular carcinoma to Transarterial chemoembolization with Lipiodol
description	Abstract Background Transarterial chemoembolization (TACE) is an effective locoregional therapy in hepatocellular carcinoma (HCC). However, it is difficult to predict the tumour response (TR) of TACE intraprocedurally. The aim of this study was to predict the TR after TACE (1–3 months) in HCC patients using intraprocedural intraarterial contrast enhanced ultrasound (IA-CEUS). Methods In this case-control study, consecutive patients who received TACE in our hospital from September 2018 to May 2019 were enrolled. IA-CEUS was performed before and after TACE. Postoperative contrast-enhanced liver MRI was performed 1–3 months after TACE as the gold standard. According to the modified Response Evaluation Criteria in Solid Tumours (mRECIST), ultrasonic manifestations were compared between the complete remission (CR) group and non-CR group by univariate and multivariate analyses. A logistic predictive model was established and validated, and its diagnostic efficiency was evaluated. Results Forty-four patients with sixty-one lesions were enrolled in the study. Multivariate analysis identified, the risk factors as a large lesion diameter (OR: 1.84; 95% confidence interval [CI]: 1.009, 3.080; P = 0.020), a larger dimension of non-enhancing area in superior mesenteric artery (SMA)-CEUS than the size in B-mode ultrasound preoperatively (OR: 3.379; 95% CI: 1.346,8.484; P = 0.010), presence of corona enhancement in hepatic artery (HA)-CEUS postoperatively (OR: 6.642; 95% CI: 1.214, 36.331; P = 0.029), and decreased corona enhancement thickness (per centimetre) postoperatively (OR: 0.025; 95% CI: 0.006,0.718; P = 0.025). The area under the receiver operating characteristic curve (AUROC) of the predictive model was 0.904 (95% CI: 0.804, 0.966; P < 0.001). The sensitivity, specificity, accuracy, positive predictive value, and negative predictive value were 81.08, 91.67, 85.25, 93.75, and 75.86%, respectively. Leave-one-out cross-validation (LOOCV) showed that the accuracy was 77.05%. Conclusions Intraprocedural IA-CEUS can be used to predict the TR in HCC patients after TACE.
format	article
author	Jiang Bo Han Peng Zhu LianHua Fei Xiang Luo YuKun
author_facet	Jiang Bo Han Peng Zhu LianHua Fei Xiang Luo YuKun
author_sort	Jiang Bo
title	Intraarterial contrast-enhanced ultrasound to predict the short-term tumour response of hepatocellular carcinoma to Transarterial chemoembolization with Lipiodol
title_short	Intraarterial contrast-enhanced ultrasound to predict the short-term tumour response of hepatocellular carcinoma to Transarterial chemoembolization with Lipiodol
title_full	Intraarterial contrast-enhanced ultrasound to predict the short-term tumour response of hepatocellular carcinoma to Transarterial chemoembolization with Lipiodol
title_fullStr	Intraarterial contrast-enhanced ultrasound to predict the short-term tumour response of hepatocellular carcinoma to Transarterial chemoembolization with Lipiodol
title_full_unstemmed	Intraarterial contrast-enhanced ultrasound to predict the short-term tumour response of hepatocellular carcinoma to Transarterial chemoembolization with Lipiodol
title_sort	intraarterial contrast-enhanced ultrasound to predict the short-term tumour response of hepatocellular carcinoma to transarterial chemoembolization with lipiodol
publisher	BMC
publishDate	2021
url	https://doaj.org/article/3f57b64702fe474ea729e302f35fe12c
work_keys_str_mv	AT jiangbo intraarterialcontrastenhancedultrasoundtopredicttheshorttermtumourresponseofhepatocellularcarcinomatotransarterialchemoembolizationwithlipiodol AT hanpeng intraarterialcontrastenhancedultrasoundtopredicttheshorttermtumourresponseofhepatocellularcarcinomatotransarterialchemoembolizationwithlipiodol AT zhulianhua intraarterialcontrastenhancedultrasoundtopredicttheshorttermtumourresponseofhepatocellularcarcinomatotransarterialchemoembolizationwithlipiodol AT feixiang intraarterialcontrastenhancedultrasoundtopredicttheshorttermtumourresponseofhepatocellularcarcinomatotransarterialchemoembolizationwithlipiodol AT luoyukun intraarterialcontrastenhancedultrasoundtopredicttheshorttermtumourresponseofhepatocellularcarcinomatotransarterialchemoembolizationwithlipiodol
_version_	1718442415671476224

Intraarterial contrast-enhanced ultrasound to predict the short-term tumour response of hepatocellular carcinoma to Transarterial chemoembolization with Lipiodol

Ejemplares similares